Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB571 in Participants With Gastrointestinal Tumors
NCT07564466Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SKB571 in gastrointestinal tumor, gastric cancer (GC), gastroesophageal junction adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), colorectal adenocarcinoma, sponsored by Kelun-Biotech. Started May 2026; status: recruiting.
02
Drugs
SKB571
03
Conditions
gastrointestinal tumorgastric cancer (GC)gastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07564466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564466.